| Product | Indication | Preclinical | Phase One | Phase Two | Phase Three |
| Retinal Disease Programs | |||||
| KIO-301 (Intravitreal) | Retinitis Pigmentosa |
|
|
|
|
| Choroideremia |
|
|
|
||
| Stargardt’s Disease |
|
|
|
||
| KIO-104 (Intravitreal) | Posterior Non-Infectious Uveitis |
|
|
|
|
| Ancillary Anterior Segment Programs* | |||||
| KIO-101 (Eyedrop) | Ocular Presentation of Rheumatoid Arthritis + |
|
|
|
|
| KIO-201 (Eyedrop) | Persistent Corneal Epithelial Defects |
|
|
|
|
| Corneal Surgical Wounds |
|
|
|
|
|
These therapeutics are still in development and are not yet approved for commercial use.
